GeneDx (WGS) Projected to Post Earnings on Tuesday

GeneDx (NASDAQ:WGS) is anticipated to announce its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect GeneDx to announce earnings of $0.0729 per share and revenue of $122.93 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, August 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.20. The business had revenue of $114.44 million for the quarter, compared to the consensus estimate of $111.01 million. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%. During the same quarter in the previous year, the business earned $0.36 earnings per share. On average, analysts expect GeneDx to post ($0.41) EPS for the current fiscal year and $1.15 EPS for the next fiscal year.

GeneDx Price Performance

NASDAQ:WGS opened at $66.29 on Tuesday. GeneDx has a 52-week low of $32.21 and a 52-week high of $170.87. The company has a market cap of $1.98 billion, a P/E ratio of -18.21 and a beta of 1.95. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.06 and a current ratio of 3.30. The stock’s 50-day simple moving average is $81.71 and its 200 day simple moving average is $67.38.

Analysts Set New Price Targets

A number of research analysts have weighed in on WGS shares. TD Cowen restated a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. Weiss Ratings upgraded GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research note on Tuesday, August 4th. Zacks Research cut GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 9th. Canaccord Genuity Group increased their price objective on GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, BTIG Research reissued a “buy” rating and issued a $90.00 price objective on shares of GeneDx in a report on Tuesday, August 4th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $90.86.

Insider Activity

In related news, CFO Kevin Feeley sold 3,728 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $363,890.08. Following the completion of the sale, the chief financial officer directly owned 44,945 shares in the company, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $1,025,002.61. Following the transaction, the chief executive officer owned 115,476 shares of the company’s stock, valued at $11,271,612.36. The trade was a 8.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 19,206 shares of company stock worth $1,808,056 over the last 90 days. 25.17% of the stock is owned by company insiders.

GeneDx Company Profile

GeneDx (NASDAQ: WGS) is a precision health company that provides genetic testing and related data services. The company focuses on helping healthcare professionals identify genetic conditions, support diagnosis and treatment decisions, and better understand inherited disease.

Its offerings include exome and genome sequencing, testing for rare and undiagnosed disorders, hereditary cancer testing, and other genetic analyses. GeneDx also provides clinical interpretation and reporting intended to help physicians evaluate genetic results in the context of a patient’s symptoms and family history.

Founded in 2000, GeneDx has built a business around genomic testing for patients with rare diseases and other inherited conditions.